Prevalence of Gastroesophageal Reflux Disease (GERD) in Patients With Upper Gastrointestinal Track (GIT) Symptoms in Thailand

Upper GIT Symptoms Clinical Trial

— GerdQ  

Official title:

Prevalence of GERD in Patients With upperGITsymptoms in Thailand

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00999063
• Other study ID #: NIS-GTH-NEX-2009/1
• Status: Completed
• Phase: N/A
• First received: October 20, 2009
• Last updated: March 30, 2011
• Start date: December 2009
• Est. completion date: February 2011

Study information

• Verified date: March 2011
• Source: AstraZeneca
• Contact: n/a
• Is FDA regulated: No
• Health authority: Thailand: Ethical CommitteeThailand: Food and Drug AdministrationThailand: Khon Kaen University Ethics Committee for Human ResearchThailand: Ministry of Public Health
• Study type: Observational

Clinical Trial Summary

This is a prospective , epidemiological, multi-centre, phase IV study, approximately 5,000 patients who suffer with upper gastrointestinal tract symptoms. Each patient will be assessed for GERD with GerdQ Thai Version.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4108
• Est. completion date: February 2011
• Est. primary completion date: February 2011
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Provision of informed consent prior to any study specific procedures

• Female or male aged at least 18 years

• Patient must be having symptoms suggestive of upper gastrointestinal tract symptoms such as heart burn/ regurgitation

Exclusion Criteria:

• Involvement in the planning and /or conduct of the study (applies to both AstraZeneca staff and /or staff at study site

• Participation in a clinical study(excluding non-interventional study or registry) during the last 3 months

Study Design

Time Perspective: Prospective

Related Conditions & MeSH terms

• Gastroesophageal Reflux
• Upper GIT Symptoms

Locations

Country	Name	City	State
Thailand	Research Site	Bangkok Noi	Bangkok
Thailand	Research Site	Klong Luang	Pathumthani
Thailand	Research Site	Maerim	Chiang Mai
Thailand	Research Site	Maung	Chiang Mai
Thailand	Research Site	Maung	Khon Kaen
Thailand	Research Site	Maung	Nakhon Sri Thammarat
Thailand	Research Site	Maung	Nakhonratchasima
Thailand	Research Site	Maung	Nakhonsawan
Thailand	Research Site	Maung	Nakornpathom
Thailand	Research Site	Maung	Phetchabun
Thailand	Research Site	Maung	Phuket
Thailand	Research Site	Maung	Rajburi
Thailand	Research Site	Maung	Roiet
Thailand	Research Site	Maung	Samut sakorn
Thailand	Research Site	Maung	Sukhothai
Thailand	Research Site	Maung	Trang
Thailand	Research Site	Maung	Ubonratchathani
Thailand	Research Site	Maung	Uttaradit
Thailand	Research Site	Muang	Udon Thani
Thailand	Research Site	Muang	Bangkok
Thailand	Research Site	Muang	Nonthaburi
Thailand	Research Site	Pathumwan	Bangkok
Thailand	Research Site	Rajthevee	Bangkok
Thailand	Research Site	Ratchthewi	Bangkok
Thailand	Research Site	Varin Chamrap	Ubonratchathani

Sponsors (1)

Lead Sponsor	Collaborator
AstraZeneca

Country where clinical trial is conducted

Thailand, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Prevalence of gastroesophageal reflux disease (GERD) in patients presented with upper gastrointestinal tract symptoms			No
Secondary	Response to various treatments for patients who have been diagnosed of GERD			No